Managing Vaccine Schedules

1. What is the patient's age? Default: [REQUIRED]
2. What is the patient's immunization history (from IIS, patient records, or international records)? Default: query IIS
3. Are there any vaccine contraindications (severe allergic reaction to prior dose or component, immunocompromised state, pregnancy)? Default: screen
4. Is the patient immunocompromised (HIV, transplant, biologics, chemotherapy, primary immunodeficiency)? Default: per history
5. Is the patient pregnant or planning pregnancy? Default: no
6. Has the patient traveled internationally or planning travel? Default: no
7. Are there vaccine hesitancy concerns to address? Default: assess
8. What is the patient's insurance coverage for vaccines (VFC-eligible, private, Medicare Part D)? Default: per coverage

Documents to Request

• State Immunization Information System (IIS) printout
• Patient-held immunization record card
• International vaccination records with translation if needed
• Prior adverse event documentation (VAERS reports if applicable)
• Allergy history (especially egg, gelatin, neomycin, yeast, latex, PEG)
• Immunocompromised status documentation (CD4 count if HIV, transplant medication list)
• Pregnancy status (LMP and EDD if pregnant)
• Travel itinerary if travel vaccines needed
• Insurance/VFC eligibility verification

Step 1: Childhood Immunization Schedule (0-18 Years)

CDC/ACIP 2024 Recommended Schedule:

Minimum intervals (critical for catch-up):

• Minimum intervals must be met for a dose to count; doses administered too early must be repeated
• Example: DTaP doses 1-3 minimum 4 weeks apart; dose 3 to 4 minimum 6 months; dose 4 to 5 minimum 6 months
• Use CDC catch-up schedule table or immunization calculation tools (e.g., CDC's Catch-Up Immunization Scheduler)

Step 2: Adult Immunization Schedule (≥19 Years)

CDC/ACIP 2024 Recommended Adult Schedule:

Step 3: Contraindication and Precaution Screening

True contraindications (vaccine MUST NOT be given):

Precautions (may defer; assess risk-benefit):

• Moderate-to-severe acute illness with or without fever → defer until improved
• Recent blood products → defer live vaccines per interval table (e.g., 3 months after IVIG)
• History of Guillain-Barré syndrome within 6 weeks of prior dose → assess risk-benefit for influenza, Tdap
• Thrombocytopenia → assess risk-benefit for MMR (can cause transient thrombocytopenia)

NOT contraindications (vaccines CAN be given):

• Mild illness with or without low-grade fever
• Current antibiotic therapy
• Prematurity (vaccinate per chronologic age)
• Breastfeeding
• Family history of adverse reactions
• Allergies to eggs (for influenza: can give any vaccine to any egg-allergic patient per ACIP 2023; observe 30 min if severe egg allergy)

Step 4: Catch-Up Immunization Protocol

Process for under-immunized patients:

1. Obtain all available records (IIS, patient card, international records, provider records)
2. Inventory: list all documented doses with dates
3. Evaluate: determine which doses are valid (met minimum age and minimum interval)
4. Identify gaps: compare against recommended schedule
5. Create catch-up plan using CDC catch-up schedule:
   • Do NOT restart a series; credit all prior valid doses
   • Apply minimum intervals (not recommended intervals) for catch-up
   • Administer as many vaccines as possible at each visit (no maximum number)
   • Schedule return visits at minimum interval for next doses due

Common catch-up scenarios:

Step 5: Documentation, Reporting, and Hesitancy Management

Required documentation for every vaccine administered:

• Vaccine name, manufacturer, lot number, expiration date
• Dose number in series (e.g., DTaP #3 of 5)
• Route and site of administration (IM deltoid, IM anterolateral thigh, SC)
• Date and time administered
• Name and title of person administering
• VIS (Vaccine Information Statement) date and date provided to patient/parent
• Informed consent documented
• Adverse reaction monitoring period completed (15-30 minutes per vaccine)

State IIS reporting:

• Report within 24-72 hours per state requirement (many states mandate same-day electronic reporting)
• Include all required data fields per state IIS specifications
• Query IIS before every vaccination visit to prevent duplicate doses

VAERS reporting:

• Report any adverse event listed on the VAERS Table of Reportable Events
• Report any clinically significant adverse event even if not on the table
• VAERS reports can be filed by anyone: clinicians, patients, parents

Vaccine hesitancy management:

• Use presumptive language: "Today we'll be giving the [vaccine name]" rather than "Would you like the vaccine?"
• Listen to concerns without judgment; acknowledge emotions
• Address specific concerns with evidence (e.g., MMR does not cause autism per extensive evidence; vaccine ingredients are in trace amounts)
• Use motivational interviewing techniques; avoid confrontation
• Document vaccine refusal with specific vaccines refused, counseling provided, risks discussed, and parent/patient signature if possible
• Offer to revisit at next visit; do not dismiss patients from practice for vaccine refusal (per AAP guidance)

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Has the patient's immunization history been verified against state IIS?
2. Are all due vaccines identified with specific dose numbers and series positions?
3. Have contraindications and precautions been screened and documented?
4. Is the catch-up plan using minimum intervals (not recommended intervals)?
5. Are VIS dates documented for each vaccine administered?

Quality Audit

• State IIS queried before vaccination and results reconciled with patient records
• All due vaccines identified per age-appropriate schedule (child or adult)
• Contraindication screening completed and documented (allergy history, immune status, pregnancy)
• Vaccine Information Statements (VIS) provided for each vaccine with date documented
• Each vaccine documented with: name, manufacturer, lot number, expiration date, dose, route, site, administrator
• Catch-up plan created with minimum intervals for any missed doses
• No invalid doses administered (minimum age and minimum interval met)
• Live vaccine spacing rule applied (if not given same day, space ≥28 days between live vaccines)
• Immunocompromised patients assessed for live vaccine eligibility
• Pregnancy status verified before administering live vaccines
• State IIS updated within required reporting timeframe
• Adverse event monitoring period observed (15 min standard; 30 min if prior allergic reaction history)
• Vaccine hesitancy addressed with evidence-based counseling and documented
• Vaccine refusal documented with specific vaccines refused, risks discussed, and patient/parent acknowledgment
• Next vaccine visit scheduled with specific vaccines due at that visit

Guidelines

• Never restart a vaccine series because of an extended interval between doses; all prior valid doses count regardless of time elapsed since the last dose
• Live vaccines (MMR, varicella, LAIV, rotavirus) must either be given on the same day OR separated by ≥28 days; inactivated vaccines have no spacing requirements relative to each other or to live vaccines
• Egg allergy (including severe/anaphylactic) is NO longer a contraindication to any influenza vaccine per ACIP 2023 update; all patients can receive any age-appropriate influenza vaccine
• Vaccine doses administered ≤4 days before the minimum age or minimum interval ("grace period") are generally counted as valid; doses given ≥5 days early must be repeated
• Immunocompromised patients should NOT receive live vaccines but SHOULD receive all inactivated vaccines (often need higher doses or additional doses, e.g., HepB)
• Tdap is recommended during every pregnancy (27-36 weeks gestation, optimally early in this window) regardless of prior Tdap history to maximize neonatal pertussis protection
• HPV vaccine is most effective before sexual debut; all adolescents should receive the first dose at age 11-12, with strong recommendation framing it as cancer prevention
• Document ALL vaccine refusals with specific vaccines refused, evidence-based counseling provided, risks of non-vaccination discussed, and plan for re-addressing at future visits